Immunotech Biopharm Ltd (HK:6978) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immunotech Biopharm Ltd has announced that its CAR-T-19 Injection, designed for young patients with relapsed or refractory B-cell acute lymphoblastic leukemia, has received breakthrough therapy designation from China’s National Medical Products Administration. This designation is expected to fast-track the drug’s clinical development, providing early access to patients. The company’s focus on innovative cellular immunotherapy continues to drive its progress in the biopharmaceutical landscape.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.